Additional factors, such as Telomerase Reverse Transcriptase (TERT) promoter mutations, may further modulate its predictive power, emphasizing the need for a more comprehensive biomarker-driven approach to glioblastoma treatment. This evidence concerns the gene TERT and glioblastoma.